ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULE-1-DEPENDENT AND LEUKOCYTE (CD11/CD18)-DEPENDENT MECHANISMS CONTRIBUTE TO POLYMORPHONUCLEAR LEUKOCYTE ADHESION TO CYTOKINE-ACTIVATED HUMAN VASCULAR ENDOTHELIUM
- 1 April 1989
- journal article
- research article
- Vol. 142 (7) , 2257-2263
Abstract
We have examined the contributions of endothelial-leukocyte adhesion molecule-1 (ELAM-1) and the complex of leukocyte surface adehsion molecules designated CD11/CD18 to the adhesion of human polymorphonuclear leukocytes (PMN) to cultured human endothelial cells (HEC), activated by rIL-1.beta. for 4 or 24 h. Inhibition of PMN attachment to IL-1-activated HEC was measured in a quantitative in vitro monolayer adhesion assay, after treatment with mAb directed to ELAM-1 (mAb H18/7), and to CD11a (mAb L11), CD11b (mAb 44), CD11c (mAb L29), and CD18 (mAb 10F12), alone or in combination. Pretreatment of activated HEC with mAb H18/7 inhibited PMN adhesion by 47 .+-. 8% whereas control mAb had no effect. CD11/CD18-directed mAb significantly blocked PMN adhesion to activated HEC (anti-CD11a, 40 .+-. 3%; anti-CD11b, 34 .+-. 4%; anti-CD18, 78 .+-. 6% inhibition). The combination of mAb H18/7 and each of the various anti-CD11/CD18 mAb resulted in greater inhibition of PMN adhesion than any Mab alone. After 24 h or rIL-1.beta. treatment, when ELAM-1 was markedly decreased but elevated PMN adhesion was still observed, mAb H18/7 had no effect on PMN adhesion. At this time, CD11/CD18-dependent adhesive mechanisms predominated and a CD11c-dependent mechanism became apparent (anti-CD11a, 67 .+-. 4% inhibition; anti-CD11b, 45 .+-. 9%; anti-CD11c, 26 .+-. 6%; anti-CD18, 97 .+-. 1%). In summary, PMN adhesion to IL-1-activated HEC involves both CD11/CD18-dependent mechanisms and an ELAM-1-dependent mechanism, and the relative contribution of these varies at different times of IL-1-induced HEC activation. The additive blocking observed at 4 h with mAb H18/7 in combination with CD11/CD18-directed Mab implies that members of the CD11/CD18 complex do not function as an obligate ligand(s) for ELAM-1.This publication has 37 references indexed in Scilit:
- A monoclonal antibody-defined membrane antigen complex is required for neutrophil-neutrophil aggregationBlood, 1985
- Deficiency of a leukocyte surface glycoprotein (LFA-1) in two patients with Mo1 deficiency. Effects of cell activation on Mo1/LFA-1 surface expression in normal and deficient leukocytes.Journal of Clinical Investigation, 1984
- ABSENCE OF MONOCLONAL-ANTIBODY-DEFINED PROTEIN COMPLEX IN BOY WITH ABNORMAL LEUCOCYTE FUNCTIONThe Lancet, 1984
- Deficiency of a surface membrane glycoprotein (Mo1) in man.Journal of Clinical Investigation, 1984
- A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.The Journal of Experimental Medicine, 1983
- Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol).Journal of Clinical Investigation, 1983
- Characterization of Monoclonal Antibodies Against Cell Surface Molecules Associated with Cytotoxic Activity of Natural and Activated Killer Cells and Cloned CTL LinesHybridoma, 1983
- Deficiency of a Granulocyte-Membrane Glycoprotein (gp150) in a Boy with Recurrent Bacterial InfectionsNew England Journal of Medicine, 1982
- STUDIES ON THE INTERACTION BETWEEN GP-180-DEFICIENT NEUTROPHILS AND VASCULAR ENDOTHELIUM1982
- An Inherited Abnormality of Neutrophil AdhesionNew England Journal of Medicine, 1980